This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grottoli, S. Articles by Ghigo, E. Search for Related Content PubMed PubMed Citation Articles by Grottoli, S. Articles by Ghigo, E. Related Collections Neuroendocrinology and Pituitary

Cortistatin-17 and Somatostatin-14 Display the Same Effects on Growth Hormone, Prolactin, and Insulin Secretion in Patients with Acromegaly or Prolactinoma

Department of Internal Medicine, Division of Endocrinology and Metabolism (S.G., V.G., F.B., R.B., F.R., F.G., A.M., F.P., E.G.), and Department of Anatomy, Pharmacology and Forensic Medicine (G.M.), University of Turin, 10126 Turin, Italy

Address all correspondence and requests for reprints to: E. Ghigo, M.D., Division of Endocrinology and Metabolism, Department of Internal Medicine, San Giovanni Battista–Molinette Hospital, C.so Dogliotti 14, 10126 Torino, Italy. E-mail: ezio.ghigo{at}unito.it.

Context: Cortistatin binds all somatostatin receptor subtypes but also has particular central actions; moreover, a specific cortistatin receptor has also been discovered.

Objective: We compared the endocrine effects of cortistatin-17 with those of somatostatin-14 in patients with acromegaly (ACRO) or prolactinoma (PRLOMA). Normal subjects (NS) were studied as control group.

Design: All subjects underwent the following tests: 1) saline, 2) somatostatin-14 (2.0 µg/kg·h iv, 0–120 min) and 3) cortistatin-17 (2.0 µg/kg·h iv, 0–120 min) infusion.

Results: Cortistatin-17 and somatostatin-14 inhibited GH secretion to the same extent in ACRO (P < 0.05) and NS (P < 0.01). Cortistatin-17 and somatostatin-14 inhibited PRL secretion in PRLOMA (P < 0.05), to some extent in ACRO (P value not significant), but not in NS. Insulin secretion was inhibited by both cortistatin-17 and somatostatin-14 to the same extent in all groups (P < 0.05).

Conclusions: Cortistatin-17 and somatostatin-14 display the same effects on GH, PRL, and insulin secretion in patients with ACRO or PRLOMA.

This article has been cited by other articles:

				R. M. Luque and R. D. Kineman Gender-Dependent Role of Endogenous Somatostatin in Regulating Growth Hormone-Axis Function in Mice Endocrinology, December 1, 2007; 148(12): 5998 - 6006. [Abstract] [Full Text] [PDF]

				R Giordano, A Picu, L Bonelli, F Broglio, F Prodam, S Grottoli, G Muccioli, E Ghigo, and E Arvat The activation of somatostatinergic receptors by either somatostatin-14 or cortistatin-17 often inhibits ACTH hypersecretion in patients with Cushing's disease Eur. J. Endocrinol., October 1, 2007; 157(4): 393 - 398. [Abstract] [Full Text] [PDF]

				H. Rubinfeld, M. Hadani, G. Barkai, J. E. Taylor, M. D. Culler, and I. Shimon Cortistatin Inhibits Growth Hormone Release from Human Fetal and Adenoma Pituitary Cells and Prolactin Secretion from Cultured Prolactinomas J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2257 - 2263. [Abstract] [Full Text] [PDF]